158 related articles for article (PubMed ID: 15784260)
1. Molecular crowding limits the role of fetal hemoglobin in therapy for sickle cell disease.
Rotter M; Aprelev A; Adachi K; Ferrone FA
J Mol Biol; 2005 Apr; 347(5):1015-23. PubMed ID: 15784260
[TBL] [Abstract][Full Text] [Related]
2. Crowding and the polymerization of sickle hemoglobin.
Ferrone FA; Rotter MA
J Mol Recognit; 2004; 17(5):497-504. PubMed ID: 15362110
[TBL] [Abstract][Full Text] [Related]
3. Sickling of nucleated erythroid precursors from patients with sickle cell anemia.
Hasegawa S; Rodgers GP; Dwyer N; Noguchi CT; Blanchette-Mackie EJ; Uyesaka N; Schechter AN; Fibach E
Exp Hematol; 1998 Apr; 26(4):314-9. PubMed ID: 9546314
[TBL] [Abstract][Full Text] [Related]
4. Intracellular polymerization of sickle hemoglobin: disease severity and therapeutic goals.
Noguchi CT; Rodgers GP; Schechter AN
Prog Clin Biol Res; 1987; 240():381-91. PubMed ID: 3615501
[TBL] [Abstract][Full Text] [Related]
5. Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease.
Maier-Redelsperger M; Noguchi CT; de Montalembert M; Rodgers GP; Schechter AN; Gourbil A; Blanchard D; Jais JP; Ducrocq R; Peltier JY
Blood; 1994 Nov; 84(9):3182-8. PubMed ID: 7524767
[TBL] [Abstract][Full Text] [Related]
6. Sickle cell anemia: targeting the role of fetal hemoglobin in therapy.
Coleman E; Inusa B
Clin Pediatr (Phila); 2007 Jun; 46(5):386-91. PubMed ID: 17556734
[TBL] [Abstract][Full Text] [Related]
7. Established and experimental treatments for sickle cell disease.
De Franceschi L; Corrocher R
Haematologica; 2004 Mar; 89(3):348-56. PubMed ID: 15020275
[TBL] [Abstract][Full Text] [Related]
8. The kinetics of nucleation and growth of sickle cell hemoglobin fibers.
Galkin O; Nagel RL; Vekilov PG
J Mol Biol; 2007 Jan; 365(2):425-39. PubMed ID: 17069853
[TBL] [Abstract][Full Text] [Related]
9. Fetal hemoglobin in sickle cell anemia: a glass half full?
Steinberg MH; Chui DH; Dover GJ; Sebastiani P; Alsultan A
Blood; 2014 Jan; 123(4):481-5. PubMed ID: 24222332
[TBL] [Abstract][Full Text] [Related]
10. Genetic correction of sickle cell disease: insights using transgenic mouse models.
Blouin MJ; Beauchemin H; Wright A; De Paepe M; Sorette M; Bleau AM; Nakamoto B; Ou CN; Stamatoyannopoulos G; Trudel M
Nat Med; 2000 Feb; 6(2):177-82. PubMed ID: 10655106
[TBL] [Abstract][Full Text] [Related]
11. Flexibility and nucleation in sickle hemoglobin.
Ivanova M; Jasuja R; Krasnosselskaia L; Josephs R; Wang Z; Ding M; Horiuchi K; Adachi K; Ferrone FA
J Mol Biol; 2001 Dec; 314(4):851-61. PubMed ID: 11734002
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic perspectives of sickle cell anemia].
Beuzàrd Y
Rev Prat; 1992 Oct; 42(15):1908-11. PubMed ID: 1362468
[TBL] [Abstract][Full Text] [Related]
13. Sickle-cell haemoglobin polymerization: is it the primary pathogenic event of sickle-cell anaemia?
Vekilov PG
Br J Haematol; 2007 Oct; 139(2):173-84. PubMed ID: 17897293
[TBL] [Abstract][Full Text] [Related]
14. Fetal hemoglobin in sickle cell anemia: Bayesian modeling of genetic associations.
Sebastiani P; Wang L; Nolan VG; Melista E; Ma Q; Baldwin CT; Steinberg MH
Am J Hematol; 2008 Mar; 83(3):189-95. PubMed ID: 17918249
[TBL] [Abstract][Full Text] [Related]
15. Reaction of nitrite with human fetal oxyhemoglobin: a model simulation study with implications for blood flow regulation in sickle cell disease (SCD).
Salhany JM
Blood Cells Mol Dis; 2010; 44(2):111-4. PubMed ID: 19942462
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiologically based drug treatment of sickle cell disease.
Steinberg MH
Trends Pharmacol Sci; 2006 Apr; 27(4):204-10. PubMed ID: 16530854
[TBL] [Abstract][Full Text] [Related]
18. Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease.
Hebert N; Rakotoson MG; Bodivit G; Audureau E; Bencheikh L; Kiger L; Oubaya N; Pakdaman S; Sakka M; Di Liberto G; Chadebech P; Vingert B; Pirenne F; Galactéros F; Cambot M; Bartolucci P
Am J Hematol; 2020 Nov; 95(11):1235-1245. PubMed ID: 32681733
[TBL] [Abstract][Full Text] [Related]
19. [Genetic modifiers of homozygous sickle cell disease].
Hartmann K; Kulozik AE
Klin Padiatr; 2006; 218(3):170-3. PubMed ID: 16688674
[TBL] [Abstract][Full Text] [Related]
20. Intracellular polymerization of sickle hemoglobin. Effects of cell heterogeneity.
Noguchi CT; Torchia DA; Schechter AN
J Clin Invest; 1983 Sep; 72(3):846-52. PubMed ID: 6886006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
